ArticleFrontiers in neurology2025
Value of the spot sign combined with the blend sign for predicting the outcome of patients with intracerebral hemorrhage who have undergone stereotactic minimally invasive surgery.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The "brush sign": a novel and accessible CT marker for hematoma expansion in hypertensive intracerebral hemorrhage.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the effect of combining the computed tomographic angiography (CTA) spot sign with the computed tomography (CT) blend sign for predicting the outcome of patients with intracerebral hemorrhage (ICH) who have undergone stereotactic minimally invasive surgery (sMIS). Methods: Patients with ICH treated with sMIS between January 2018 and April 2023 at the affiliated hospital of Guizhou Medical University were retrospectively included. A modified Rankin scale (mRS) score of ≥3 at 3 months was defined as a poor outcome. According to neurological recovery, patients were assigned to either the poor outcome (90 patients) or the good outcome (105 patients) groups. The value of the combined signs in predicting the outcome of patients with ICH who have undergone sMIS was analyzed via the receiver operating characteristic (ROC) curve. Results: Among a total of 195 patients, 29 (14.8%) had single blend signs, 35 (17.9%) had single spot signs, 76 (39%) had combined signs, and 55 (28.2%) had CT-negative. A multivariate binary logistic regression analysis revealed that the spot sign combined with the blend sign (OR = 5.244, 95% CI: 2.606-10.55, Conclusion: The spot sign combined with the blend sign and hematoma topography may have predictive value for outcomes in patients with ICH undergoing sMIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.